Lung mass overview

Jump to navigation Jump to search

Lung Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Causes

Differentiating Lung Mass from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Diagnosis

Diagnostic Study of Choice

Evaluation of Lung Mass

Imaging of Lung Mass

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Lung mass overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lung mass overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lung mass overview

CDC on Lung mass overview

Lung mass overview in the news

Blogs on Lung mass overview

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Lung mass overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Lung mass (also known as "Pulmonary mass") is generally defined as any area of pulmonary opacification that measures more than 30 mm in the lung. Abnormal growths found in the lung can be benign or malignant. Lung masses may be classified according to location, imaging features, size, and distribution. The most common cause of a pulmonary mass is lung cancer. Other causes, include: granuloma, dystrophic calcifications, tuberculosis, and fungus ball. The prevalence of lung masses is approximately 58 per 100,000 individuals. Lung masses have a wide age distribution. However, the majority of these lesions are more often diagnosed in adults. The most common symptom of a lung mass is cough, which will gradually persist over time. Other symptoms may include: dyspnea, hemoptysis, chronic coughing, wheezing, and chest pain. In some cases, lung masses may be asymptomatic.

Classification

Lung masses may be classified according to location, imaging features, size, and distribution.

Causes

Lung masses may be idiopathic or caused by precursor lesions. Precursor lesions for some lung masses, may include: infections, metaplasia, hamartomatous formation, or displasia.

Differential Diagnosis

Lung masses may be differentiated according to clinical features, laboratory findings, imaging features, histological features, and genetic studies, from other diseases that cause cough, chest pain, or wheezing. Common differential diagnosis includes: lung cancer, tuberculosis, pulmonary abscess, granulomas, loculated pleural effusion, and metastases.

Epidemiology and Demographics

The incidence rate of lung masses is approximately 58 per 100 000 individuals in the United States. The incidence of lung masses increases with age; the median age at diagnosis is between 35 to 75 years. Males are more commonly affected with lung masses than females. The male to female ratio is approximately 2 to 1. There is no racial predilection for lung masses.

Screening

According to the U.S. Preventive Services Task Force (USPSTF) there is sufficient evidence to recommend routine screening for lung masses. Screening for suspected lung cancer by low-dose computed tomography is recommended every year among smokers who are between 55 to 80 years old and who have history of smoke 30 pack-years or more and either continue to smoke or have quit within the past 15 years (grade B recommendation).[1][2][3]

Diagnosis

Evaluation of Lung Mass

The evaluation of lung mass will depend on detailed medical history, age, morphology of the lesion, size, distribution.

Imaging

Conventional radiography is initial method of choice for the diagnosis of lung masses. The evaluation lung masses will depend on several characteristics, such as: size, pattern, presence of calcifications, attenuation, location, and previous imaging studies. CT is the gold standard for the complete evaluation of lung masses.

Staging

According to the American Joint Committee on Cancer (AJCC) staging system, there are 4 stages of malignant lung masses, based on 3 factors: tumor size, lymph node invasion, and metastasis.[4] Each stage is assigned a letter and a number that designate T for tumor size, N for node invasion, and M for metastasis.

History and Symptoms

Lung masses are generally asymptomatic. The majority of patients may develop non-specific symptoms, such as: dyspnea, hemoptysis, chronic coughing, wheezing, and chest pain. Obtaining the detailed history is an important aspect of making a diagnosis of lung masses, specific areas of focus when obtaining the history, are personal history of cancer, family history of lung cancer, previous infections, recent hospitalization, .[5]

Physical Examination

Physical examination findings of lung masses will depend on the location of the tumor. Common physical examination findings, include: reduced chest expansion, crackling or bubbling noises, decreased/absent breath sounds, and whispered pectoriloquy.[6]

Laboratory Studies

Laboratory findings consistent with the diagnosis of lung masses, may include: elevated LDH, elevated alkaline phosphatase (related with prognosis), and elevated aspartate aminotransferase (AST).[7]

References

  1. Lung Cancer: Screening http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening. Accessed on February 3, 2016
  2. Davis AM, Cifu AS. Lung Cancer Screening. JAMA. 2014;312(12):1248-1249. doi:10.1001/jama.2014.12272.
  3. National Lung Screening Trial. Wikipedia. https://en.wikipedia.org/wiki/National_Lung_Screening_Trial Accessed on February 4,2016
  4. Stages of non–small cell lung cancer. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/lung/staging/?region=ab
  5. Hakim DN, Pelly T, Kulendran M, Caris JA (2015). "Benign tumours of the bone: A review". J Bone Oncol. 4 (2): 37–41. doi:10.1016/j.jbo.2015.02.001. PMC 4620948. PMID 26579486.
  6. Hyde L, Hyde CI (1974). "Clinical manifestations of lung cancer". Chest. 65 (3): 299–306. PMID 4813837.
  7. Tsukushi S, Katagiri H, Kataoka T, Nishida Y, Ishiguro N (2006). "Serum tumor markers in skeletal metastasis". Jpn. J. Clin. Oncol. 36 (7): 439–44. doi:10.1093/jjco/hyl046. PMID 16815865.


Template:WikiDoc Sources